Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
SVNT [NASD]
Savient Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.53 Insider Own1.70% Shs Outstand71.67M Perf Week5.71%
Market Cap53.03M Forward P/E- EPS next Y-0.78 Insider Trans-10.37% Shs Float71.73M Perf Month32.14%
Income-108.60M PEG- EPS next Q-0.31 Inst Own47.00% Short Float18.53% Perf Quarter-1.33%
Sales19.20M P/S2.76 EPS this Y-14.40% Inst Trans-16.97% Short Ratio19.42 Perf Half Y-41.73%
Book/sh-2.26 P/B- EPS next Y36.60% ROA-81.40% Target Price1.00 Perf Year-1.33%
Cash/sh0.96 P/C0.77 EPS next 5Y- ROE89.40% 52W Range0.48 - 2.95 Perf YTD-29.52%
Dividend- P/FCF- EPS past 5Y-12.20% ROI-115.00% 52W High-74.92% Beta2.34
Dividend %- Quick Ratio3.50 Sales past 5Y5.20% Gross Margin-26.00% 52W Low54.17% ATR0.08
Employees122 Current Ratio3.60 Sales Q/Q34.30% Oper. Margin-570.80% RSI (14)54.80 Volatility15.01% 12.18%
OptionableYes Debt/Eq- EPS Q/Q30.60% Profit Margin-565.10% Rel Volume0.35 Prev Close0.74
ShortableYes LT Debt/Eq- EarningsMay 20 Payout- Avg Volume684.49K Price0.74
Recom3.30 SMA2011.11% SMA506.51% SMA200-37.12% Volume242,746 Change0.00%
26-Mar-12Initiated Canaccord Genuity Hold $2
10-Nov-11Downgrade JMP Securities Mkt Perform → Mkt Underperform $1.50
03-Oct-11Upgrade Summer Street Research Sell → Neutral
05-May-11Downgrade JMP Securities Mkt Outperform → Mkt Perform
01-Dec-10Reiterated Wedbush Outperform $16 → $17
27-Oct-10Downgrade JMP Securities Mkt Outperform → Mkt Perform
26-Oct-10Reiterated Wedbush Outperform $25 → $16
16-Sep-10Downgrade Oppenheimer Outperform → Perform
15-Sep-10Reiterated Wedbush Outperform $20 → $25
15-Sep-10Reiterated JMP Securities Mkt Outperform $20 → $26
28-Jan-10Initiated Soleil Buy $21
09-Oct-09Upgrade Oppenheimer Perform → Outperform $17
16-Sep-09Reiterated Leerink Swann Outperform $15 → $18
04-Aug-09Downgrade Jefferies & Co Hold → Underperform $5
17-Jun-09Upgrade Oppenheimer Underperform → Perform
17-Jun-09Initiated JMP Securities Mkt Outperform $15
15-Jun-09Upgrade Wall Street Access Hold → Buy $8 → $13
10-Jun-09Reiterated Wedbush Morgan Buy $31 → $15
19-Dec-08Initiated Roth Capital Buy $7
25-Nov-08Reiterated Leerink Swann Outperform $13
14-Jun-13 10:02AM  SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
13-Jun-13 12:58PM  InPlay: Savient Pharma: SPike being attributed to SEC filing as co announces price hike for KRYSTEXXA to $5.390 Briefing.com +12.86%
12:57PM  Savient increases price of Krystexxa to $5,390 per vial at theflyonthewall.com
05:51AM  SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
12-Jun-13 08:00AM  Savient Pharmaceuticals to Present New KRYSTEXXA® Data at the 2013 European League Against Rheumatism (EULAR) Congress PR Newswire
06-Jun-13 06:09PM  Nasdaq stocks posting largest volume increases AP -8.33%
11:23AM  5 Names Seeing Bullish Flow at TheStreet
05-Jun-13 06:06PM  Nasdaq stocks posting largest volume increases AP +29.23%
21-May-13 01:04PM  SAVIENT PHARMACEUTICALS INC Financials EDGAR Online Financials
20-May-13 02:50PM  SVNT July Options Begin Trading at TheStreet
19-May-13 11:40AM  3 Pharmaceutical Stock Earnings Snapshots at Wall St. Cheat Sheet
17-May-13 05:26AM  Savient downgraded to Market Perform from Outperform at William Blair theflyonthewall.com
15-May-13 08:37AM  Savient Pharmaceuticals Earnings: Everything You Must Know Now at Wall St. Cheat Sheet -14.71%
07:09AM  InPlay: Savient Pharma misses by $0.03, misses on revs Briefing.com
07:00AM  Savient Pharmaceuticals Reports First Quarter 2013 Financial Results PR Newswire
12:13AM  SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
12:11AM  SAVIENT PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
10-Apr-13 11:03PM  SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or EDGAR Online
05-Apr-13 01:04PM  SAVIENT PHARMACEUTICALS INC Financials EDGAR Online Financials
01-Apr-13 09:16AM  SAVIENT PHARMACEUTICALS INC Files SEC form 10-K, Annual Report EDGAR Online
25-Mar-13 03:32PM  Savient Pharmaceuticals: Is Anything Left? at Seeking Alpha
23-Mar-13 01:45PM  Did These 5 Stocks Miss or Beat Analyst Expectations? at Wall St. Cheat Sheet
21-Mar-13 12:03AM  SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
20-Mar-13 07:35PM  New Star Analyst Rankings for Savient Pharmaceuticals Inc StarMine
19-Mar-13 01:56PM  Savient Pharma falls on slower gout drug growth AP -14.94%
12:26PM  Savient Pharmaceuticals' CEO Discusses Q4 2012 Results - Earnings Call Transcript at Seeking Alpha
10:18AM  Savient Pharmaceuticals Earnings: Heres Why Investors are Not Happy Now at Wall St. Cheat Sheet
07:00AM  Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results PR Newswire
18-Mar-13 03:24PM  Companies reporting Before the Market Open on Tuesday, March 19 at theflyonthewall.com
26-Feb-13 08:30AM  Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013 PR Newswire
19-Feb-13 08:34AM  Sobi, Savient announce co-promotion agreement for Kineret in U.S. theflyonthewall.com
08:33AM  Sobi and Savient Pharmaceuticals Announce Co-Promotion Agreement for Kineret® (anakinra) in the U.S. Thomson Reuters ONE
08:32AM  InPlay: Savient Pharma and Sobi announce co-promotion agreement for Kineret (anakinra) in the U.S. Briefing.com
08:30AM  Sobi and Savient Pharmaceuticals Announce Co-Promotion Agreement for Kineret® (anakinra) in the U.S. PR Newswire
14-Feb-13 08:20AM  Sharp Increase in FDA Drug Approvals a Major Factor in Biotech Industry's Success Marketwire
11-Feb-13 01:58PM  5 Medical Stock Losers From Last Week With High Short Ratios at Seeking Alpha
23-Jan-13 08:20AM  Merger and Acquisition Activity Expected to Rise in 2013 as Big Pharma Companies Flush With Cash Marketwire
13-Jan-13 03:04PM  Savient Pharma: The Ultimate Biotech Option at Seeking Alpha
06:34AM  Dendreon: Foolish Management Review at Motley Fool
10-Jan-13 04:03PM  Savient Pharmaceuticals' CEO Presents at 31st Annual J.P. Morgan Healthcare Conference (Transcript) at Seeking Alpha
08-Jan-13 04:27PM  SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
11:43AM  InPlay: Savient Pharma: KRYSTEXXA (pegloticase) receives European Commission Marketing Authorization for the treatment of certain patients with chronic tophaceous gout Briefing.com
11:42AM  Savient's KRYSTEXXA® (pegloticase) Receives European Commission Marketing Authorization for the Treatment of Certain Patients with Chronic Tophaceous Gout PR Newswire
08:30AM  Savient Pharmaceuticals Announces the Election of Genzyme CEO Dr. David Meeker to Its Board of Directors PR Newswire
04-Jan-13 08:30AM  Savient Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference PR Newswire
31-Dec-12 10:18AM  SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online -7.89%
10-Dec-12 04:25PM  SAVIENT PHARMACEUTICALS INC Files SEC form 8-K/A, Results of Operations and Financial Condition, Financial Statements EDGAR Online +9.65%
05-Dec-12 08:30AM  Savient Announces the Election of Robert G. Savage to its Board of Directors PR Newswire
30-Nov-12 09:54AM  Friday Sector Leaders: Metals & Mining, Biotechnology Stocks at Forbes +9.09%
20-Nov-12 06:45PM  Savient Pharma: Still Struggling To Grow KRYSTEXXA Sales at Seeking Alpha
16-Nov-12 01:04PM  SAVIENT PHARMACEUTICALS INC Financials EDGAR Online Financials
14-Nov-12 04:27PM  SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
13-Nov-12 08:07AM  InPlay: Savient Pharma reports New data demonstrate KRYSTEXXA; risk significantly reduced the rate of IRs in the post-approval setting, as compared to rates seen during randomized clinical trials Briefing.com
08:00AM  New Data Demonstrate KRYSTEXXA®-Treated Refractory Chronic Gout Patients Experienced Significantly Improved Health-Related Quality of Life PR Newswire
12-Nov-12 08:25AM  Biotech Industry Skyrockets in 2012 as FDA Approval Rate Increases Marketwire
08:20AM  Biotech Industry Skyrockets in 2012 as FDA Approval Rate Increases Marketwire
08:08AM  InPlay: Savient Pharma announces new data published in Annals of the Rheumatic diseases confirm long-term safety and efficacy of KRYSTEXXA for the treatment of refractory chronic gout Briefing.com
08:00AM  New Data Published in Annals of the Rheumatic Diseases Confirm Long-Term Safety and Efficacy of KRYSTEXXA® for the Treatment of Refractory Chronic Gout PR Newswire
10-Nov-12 09:29AM  New Star Analyst Rankings for Savient Pharmaceuticals Inc StarMine
09-Nov-12 09:32AM  New Star Analyst Rankings for Savient Pharmaceuticals Inc StarMine
08-Nov-12 09:36PM  5 Health-Care Stocks Making Big Moves at Motley Fool -18.57%
04:15PM  SAVIENT PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
02:59PM  Savient Pharmaceuticals' CEO Discusses Q3 2012 Results - Earnings Call Transcript at Seeking Alpha
11:52AM  2 Biotech Stocks Experiencing Significant Sell-Offs Investors Should Avoid at Seeking Alpha
10:14AM  Has Savient Pharmaceuticals Become the Perfect Stock? at Motley Fool
07:10AM  InPlay: Savient Pharma misses by $0.11, misses on revs Briefing.com
07:07AM  Q3 2012 Savient Pharmaceuticals, Inc. Earnings Release - Before Market Open CCBN
07:00AM  Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results PR Newswire
25-Oct-12 07:18PM  3 Health Care Stocks Beating Todays Market at Motley Fool -9.57%
19-Oct-12 10:51AM  InPlay: Savient Pharma confirms it received a positive CHMP opinion for KRYSTEXXA approval in the EU Briefing.com
10:50AM  Savient Receives Positive CHMP Opinion for KRYSTEXXA® Approval in the EU PR Newswire
10:43AM  Pharma Stock Movements After FDA ADCOM And EU EMA Decisions This Week at Seeking Alpha
18-Oct-12 08:32PM  What Moves Biotech Stocks? Ed Arce Has Answers. at Seeking Alpha
16-Oct-12 08:20AM  Biotech Industry Looks to Benefit as FDA Speeds Up Process for Drugs for Critical Diseases Marketwire
15-Oct-12 04:01PM  Savient: Bond Prices, Stock Borrow Rates And Analysts' Target Prices Signal Challenges Ahead at Seeking Alpha
03:48PM  Savient: Bond Prices, Stock Borrow Rates And Analysts' Target Prices Signal Challenges Ahead at Seeking Alpha
11-Oct-12 09:52AM  OCZ Tech: Untouchable For Now at Seeking Alpha
09-Oct-12 01:10PM  Savient Pharmaceuticals May Continue To Run Higher at Seeking Alpha
08:32AM  Savient Pharmaceuticals' Impressive Run May Continue Higher Thomson Reuters ONE
07:30AM  Healthcare Business Report: Pfizers SEC Inquiry, Exact Sciences Potential at Wall St. Cheat Sheet
03:58AM  Healthcare Business Report: Pfizers SEC Inquiry, Exact Sciences Potential at Wall St. Cheat Sheet
08-Oct-12 07:58PM  Healthcare Business Report: Pfizers SEC Inquiry, Exact Sciences Potential at Wall St. Cheat Sheet
05:32PM  Healthcare Business Report: Pfizers SEC Inquiry, Exact Sciences Potential at Wall St. Cheat Sheet
04:04PM  Savient: The Tang Rally Is Over - What's Next at Seeking Alpha
10:41AM  H-P Break-Up Deemed Likely and 4 Stock Analyses Attracting Attention at Wall St. Cheat Sheet
02-Oct-12 09:17AM  Lessons From Biotech's Best Third Quarter Stocks at TheStreet
29-Sep-12 08:35AM  What's Fueling Savient's Run? at Motley Fool
28-Sep-12 04:09PM  Dendreon Gains After Aetna Expands Coverage of Provenge at Bloomberg +12.11%
03:09PM  Dendreon Gains After Aetna Expands Coverage of Provenge at Bloomberg
08:35AM  Biotech Industry Applauds Introduction of the High Technology Small Business Research Incentives Act Marketwire
08:27AM  Biotech Industry Applauds Introduction of the High Technology Small Business Research Incentives Act Marketwire
08:20AM  Biotech Industry Applauds Introduction of the High Technology Small Business Research Incentives Act Marketwire
27-Sep-12 04:22PM  SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E EDGAR Online -7.85%
26-Sep-12 04:50PM  Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) PR Newswire -10.37%
24-Sep-12 04:13PM  PropThink: Shorts Scramble to Cover as CFO Hire at Savient Bolsters Shares Thomson Reuters ONE +16.80%
10:47AM  Savient Pharmaceuticals hires John Hamill as CFO AP
07:36AM  Savient names John Hamill as CFO theflyonthewall.com
07:32AM  InPlay: Savient Pharma announced the appointment of John Hamill as Senior Vice President & CFO effective today Briefing.com
07:30AM  Savient Pharmaceuticals Names John P. Hamill Chief Financial Officer PR Newswire
21-Sep-12 03:28PM  These 2 Stocks Stopped the Presses at Motley Fool +9.17%
Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company in the United States. It engages in developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients refractory to conventional therapy. The company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. Savient Pharmaceuticals, Inc. sells its products through a network of specialty and wholesale distributors. The company was formerly known as Bio-Technology General Corp. and changed its name to Savient Pharmaceuticals, Inc. in June 2003. Savient Pharmaceuticals, Inc. was founded in 1980 and is headquartered in Bridgewater, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FERRARI LOUISPresident and CEOMay 22Sale0.571,020581307,439May 23 02:36 PM
CROWLEY RichardEVP, Chief Operating OfficerApr 30Sale0.742,4851,839285,490May 01 05:36 PM
Bahrt KennethSVP, Chief Medical OfficerApr 30Sale0.741,250925178,211May 01 05:37 PM
Gionco DavidGroup VP & Chief Acct. OfficerMar 06Sale0.931,5601,45183,640Mar 08 04:15 PM
FERRARI LOUISPresident and CEOFeb 25Sale0.99375371295,996Feb 25 04:35 PM
Bahrt KennethSVP, Chief Medical OfficerFeb 04Sale1.0329,00029,941171,750Feb 06 10:19 AM
CROWLEY RichardEVP, Biopharmaceutical OpsFeb 04Sale1.0348,90050,589287,975Feb 06 10:18 AM
FERRARI LOUISPresident and CEOFeb 04Sale1.0162,20062,854296,371Feb 06 10:17 AM
YACHMETZ PHILIP KSVP, General CounselFeb 04Sale1.0130,50030,837303,701Feb 06 10:17 AM
Bahrt KennethSVP, Chief Medical OfficerJan 31Sale1.031,3001,339200,750Feb 04 01:57 PM
CROWLEY RichardEVP, Biopharmaceutical OpsJan 31Sale1.022,4152,463336,875Feb 04 01:57 PM
YACHMETZ PHILIP KSVP, General CounselJan 14Sale1.141,2831,463334,201Jan 16 04:07 PM
FERRARI LOUISPresident and CEONov 26Sale1.169501,102358,571Nov 27 04:12 PM
CROWLEY RichardEVP, Biopharmaceutical OpsOct 31Sale1.452,0102,915339,290Nov 06 06:40 PM
Bahrt KennethSVP, Chief Medical OfficerOct 31Sale1.451,0001,450202,050Nov 06 06:39 PM
FERRARI LOUISPresident and CEOAug 22Sale1.00984986348,577Aug 24 08:05 PM
CROWLEY RichardEVP, Biopharma OperatiotionsAug 02Sale0.622,5001,550341,300Aug 03 08:38 AM
Bahrt KennethSVP, Chief Medical OfficerAug 01Sale0.624,9503,069203,050Aug 03 08:38 AM